UK earnings, trading statements calendar - next 7 days
24th Jul 2023 15:46
Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer. Read More
Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet. Read More
Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers. Read More
(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month. Read More
(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023. Read More
(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma. Read More
(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company to commercialise Hutchmed's key cancer drug outside China. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business. Read More